ABC7 | Dr.Eric P. Winer:Do a good job of managing advanced breast cancer patients

ABC7 | Dr.Eric P. Winer:Do a good job of managing advanced breast cancer patients

Since the 6th International Consensus Conference on Advanced Breast Cancer (ABC6), the field of advanced breast cancer treatment has changed a lot with the emergence of new therapeutic agents. At the 7th International Consensus Conference on Advanced Breast Cancer (ABC7), Oncology Frontier invited Dana-Farber Cancer Institute Dr.Eric P.Winer to share with us the changing treatment of breast cancer.
Dr.Hu Xichun &Hope S. Rugo: Future treatment strategies for advanced triple-negative breast cancer and HR+/ HER2-breast cancer from the perspective of ADC drug treatment progress

Dr.Hu Xichun &Hope S. Rugo: Future treatment strategies for advanced triple-negative breast cancer and HR+/ HER2-breast cancer from the perspective of ADC drug treatment progress

The International Consensus Conference on Advanced Breast Cancer (ABC) is the premier international conference in the academic field of advanced breast cancer, whose primary goal is to develop international consensus guidelines for the management of patients with advanced breast cancer. These guidelines are based on the latest evidence and can be used to guide treatment decisions in many different healthcare Settings around the world. The ABC also aims to identify research priorities based on the most important areas of unmet need, analyze and discuss existing data to provide the most accurate management recommendations, influence policymakers and funding agencies, and ultimately improve standards of care, survival, and quality of life. On the ABC7,Oncology Frontier invited Professor Hu Xichun, Affiliated Cancer Hospital of Fudan University, and Professor Hope S.Rugo, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, to present their views on the diagnosis and treatment concept of advanced triple-negative breast cancer and HR+/ HER2-breast cancer.